Shyam Masrani
Partner Medicxi
Shyam is a Partner at Medicxi. Prior to joining Medicxi, Shyam founded two early-stage biotechnology companies (Shyden Biotechnology and Cleavr Therapeutics). He led Medicxi’s investment in Merus (NASDAQ:MRUS) and ProfoundBio (acquired by Genmab) and currently serves on the boards of a number of portfolio companies, including T-Cypher Bio, My-T Bio, Acera Therapeutics, Petalion Therapeutics and CosMyc Therapeutics. Shyam obtained a BSc in Biochemistry and a Masters in Translational Medicine from Imperial College London.
Seminars
As the ADC field matures beyond the large-scale pharma M&A deal-making from 2024, there continues to be a stream of licensing and partnerships activity as the community looks to leverage novel science and technologies to develop the next generation of targeted oncology therapies. Further driven by an increasingly crowded landscape and heightened need to develop differentiated ADCs, the bar has been raised to develop novel ADCs that will be backed by life science investors and attract the attention of pharma and biotech collaborators.
Exclusively designed for search and evaluation, external evaluation, and business development leads, C level biotech leaders, and VC biopharma investors, the ADC Licensing, Partnering & Investment Panel is the place to be to understand diverse perspectives on what ADC innovation is showing most promise, how best to balance novelty versus risk to investors, and biopharma decision-maker attitudes when evaluating ADC deal-making opportunities in 2026.
Open to all registered attendees, join to be part of an insightful panel session followed by an informal networking opportunity to foster new relationships for ADC collaboration, partnerships and investment.
Panel Discussion Highlights:
- Contextualising the current state of investment and deal-making in the ADC field: What direction if the field headed as it crests the Topo1 wave?
- Breaking down different avenues for ADC differentiation to understand what is showing promise and predict where the ADC field will be in 3-5 years
- Delving into investor perspectives to help set up ADC companies in Series A funding for success
- Understanding pharma and biotech attitudes towards required data, level of risk, and differentiating factor when deciding which ADC programmes to explore licensing and partnering
- Debating the factors contributing towards the go/no-go decision in the clinic to move towards licensing and partnership conversations
